The abstract is read at the publisher; the summary is JClub's.
KIFC1 is enriched in lung cancer bone metastases and correlates with poor bone metastasis-free survival, while KIFC1 drives osteolytic tumor growth in vivo.
- Why it matters: Bone metastasis occurs in 30–40% of lung cancer patients and severely worsens survival, but the molecular pathway linking tumor cells to bone disruption is incompletely defined.
- What they did: Comparative transcriptomics of primary lung tumors and paired bone metastases identified KIFC1 enrichment; mechanistically, KIFC1 associates with RUNX2 via its C-terminal motor domain to promote RUNX2 nuclear accumulation and TGFB1 transcription, activating TGF-β/SMAD3.
- The result: Silencing RUNX2 or inhibiting SMAD3 largely abrogated KIFC1-driven pro-metastatic and pro-osteolytic effects, and in vivo KIFC1 knockdown reduced intraosseous tumor burden and trabecular bone loss.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.